Development Status

iPSC Regenerative Medicine

【Ophthalmology Area】

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCR011 Wet AMD Japan
Joint development with Sumitomo Dainippon Pharma
Undergoing preparation for clinical trial
Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status
HLCR012 Dry AMD US
EU
CRADA with NEI

【Liver Disease】

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCL041 Metabolic Liver Disease Japan
Joint research with Yokohama City University

【Immuno Oncology】

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCN061 Solid Tumors Japan
Healios is promoting R&D
Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status
HLCN061 Solid Tumors US
Healios is promoting R&D
  1. NK (Natural killer) cells : NK cells are a subset of lymphocytes, a type of white blood cell. NK cells play a central role in a cell mediated defense system that human bodies naturally have, and attack cancer cells and virus-infected cells.

Somatic Stem Cell Regenerative Medicine

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCM051 Ischemic Stroke Japan
Clinical trial (TREASURE study) ongoing
HLCM051 ARDS Japan
Clinical trial (ONE-BRIDGE study) ongoing